BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...AG (Xetra:EVT), Bristol Myers Squibb Co. (NYSE:BMY) and GT Healthcare Capital. Geron raises $150M follow-on Geron Corp....
...to this report. Targets TLR3 - Toll-like receptor 3 Robin Sawka, Staff Writer Robin Sawka, BioCentury Staff Exscientia Ltd. Geron Corp. Silence...
BioCentury | Feb 4, 2019
Company News

Management tracks: PhRMA, Amgen, Apellis

...3 (C3) inhibitor, is in Phase III testing for geographic atrophy and paroxysmal nocturnal hemoglobinuria. Geron Corp....
BioCentury | Dec 31, 2018
Company News

Management tracks: Myriad co-founder Meldrum passes away

...CEO. Cancer company Geron Corp. (NASDAQ:GERN) said Chairman Hoyoung Huh has resigned. He is succeeded by Geron...
BioCentury | Sep 28, 2018
Company News

Geron shares fall after Janssen returns imetelstat rights

...Janssen Biotech Inc. said it returned exclusive, worldwide development and commercialization rights for imetelstat to Geron Corp....
...said the decision was based on a strategic review of its portfolio. The news sent Geron...
...data from the trial's first part (see "Geron Falls on Imetelstat Update" ). On Thursday, Geron...
BioCentury | Sep 28, 2018
Company News

Geron shares fall after Janssen discontinues partnership

...Janssen Biotech Inc. said it returned exclusive, worldwide development and commercialization rights for imetelstat to Geron Corp....
...said the decision was based on a strategic review of its portfolio. The news sent Geron...
...supply imetelstat for up to 24 months during manufacturing transition (see "Geron, J&J Deal" ). Geron Corp....
BioCentury | Jan 19, 2018
Clinical News

Geron reports Phase II data of imetelstat for MDS

...mean relative reduction in transfusion burden from baseline of 71%. Based on the subgroup data, Geron...
...worldwide rights to develop and commercialize imetelstat from Geron (see BioCentury, Nov. 17, 2014 ). Geron Corp....
...rate, overall survival (OS) and progression-free survival (PFS) Status: Phase II/III data Milestone: NA Jaime De Leon GRN163L imetelstat JNJ-63935937 Geron Corp. Johnson...
BioCentury | Apr 13, 2017
Clinical News

Imetelstat: Additional Ph II IMbark data

...is an appropriate starting dose for the population, and recommended the study continue without modification. Geron...
...reported interim data from 40 patients in the trial (see BioCentury, Sept. 19, 2016 ). Geron...
...worldwide rights to develop and commercialize imetelstat from Geron (see BioCentury, Nov. 17, 2014 ). Geron Corp....
BioCentury | Apr 13, 2017
Clinical News

Imetelstat: Additional Ph II/III IMerge data

...in lower risk MDS. The Phase II portion is fully enrolled and will continue unmodified. Geron...
...the double-blind, placebo-controlled Phase III portion of the trial. If the pharma decides to proceed, Geron...
...worldwide rights to develop and commercialize imetelstat from Geron (see BioCentury, Nov. 17, 2014 ). Geron Corp....
BioCentury | Apr 10, 2017
Company News

Geron gains as imetelstat studies proceed

...has yet to determine whether it will continue development of the programs beyond upcoming milestones. Geron...
...are to evaluate spleen response rate and symptom response rate. On a conference call Monday, Geron...
...the IMbark data "during the next year." After its first internal data review last year, Geron...
BioCentury | Oct 3, 2016
Finance

Dressed in black

...the Phase III GOYA trial as first-line therapy for CD20-positive diffuse large B cell lymphoma Geron Corp....
Items per page:
1 - 10 of 564
BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...AG (Xetra:EVT), Bristol Myers Squibb Co. (NYSE:BMY) and GT Healthcare Capital. Geron raises $150M follow-on Geron Corp....
...to this report. Targets TLR3 - Toll-like receptor 3 Robin Sawka, Staff Writer Robin Sawka, BioCentury Staff Exscientia Ltd. Geron Corp. Silence...
BioCentury | Feb 4, 2019
Company News

Management tracks: PhRMA, Amgen, Apellis

...3 (C3) inhibitor, is in Phase III testing for geographic atrophy and paroxysmal nocturnal hemoglobinuria. Geron Corp....
BioCentury | Dec 31, 2018
Company News

Management tracks: Myriad co-founder Meldrum passes away

...CEO. Cancer company Geron Corp. (NASDAQ:GERN) said Chairman Hoyoung Huh has resigned. He is succeeded by Geron...
BioCentury | Sep 28, 2018
Company News

Geron shares fall after Janssen returns imetelstat rights

...Janssen Biotech Inc. said it returned exclusive, worldwide development and commercialization rights for imetelstat to Geron Corp....
...said the decision was based on a strategic review of its portfolio. The news sent Geron...
...data from the trial's first part (see "Geron Falls on Imetelstat Update" ). On Thursday, Geron...
BioCentury | Sep 28, 2018
Company News

Geron shares fall after Janssen discontinues partnership

...Janssen Biotech Inc. said it returned exclusive, worldwide development and commercialization rights for imetelstat to Geron Corp....
...said the decision was based on a strategic review of its portfolio. The news sent Geron...
...supply imetelstat for up to 24 months during manufacturing transition (see "Geron, J&J Deal" ). Geron Corp....
BioCentury | Jan 19, 2018
Clinical News

Geron reports Phase II data of imetelstat for MDS

...mean relative reduction in transfusion burden from baseline of 71%. Based on the subgroup data, Geron...
...worldwide rights to develop and commercialize imetelstat from Geron (see BioCentury, Nov. 17, 2014 ). Geron Corp....
...rate, overall survival (OS) and progression-free survival (PFS) Status: Phase II/III data Milestone: NA Jaime De Leon GRN163L imetelstat JNJ-63935937 Geron Corp. Johnson...
BioCentury | Apr 13, 2017
Clinical News

Imetelstat: Additional Ph II IMbark data

...is an appropriate starting dose for the population, and recommended the study continue without modification. Geron...
...reported interim data from 40 patients in the trial (see BioCentury, Sept. 19, 2016 ). Geron...
...worldwide rights to develop and commercialize imetelstat from Geron (see BioCentury, Nov. 17, 2014 ). Geron Corp....
BioCentury | Apr 13, 2017
Clinical News

Imetelstat: Additional Ph II/III IMerge data

...in lower risk MDS. The Phase II portion is fully enrolled and will continue unmodified. Geron...
...the double-blind, placebo-controlled Phase III portion of the trial. If the pharma decides to proceed, Geron...
...worldwide rights to develop and commercialize imetelstat from Geron (see BioCentury, Nov. 17, 2014 ). Geron Corp....
BioCentury | Apr 10, 2017
Company News

Geron gains as imetelstat studies proceed

...has yet to determine whether it will continue development of the programs beyond upcoming milestones. Geron...
...are to evaluate spleen response rate and symptom response rate. On a conference call Monday, Geron...
...the IMbark data "during the next year." After its first internal data review last year, Geron...
BioCentury | Oct 3, 2016
Finance

Dressed in black

...the Phase III GOYA trial as first-line therapy for CD20-positive diffuse large B cell lymphoma Geron Corp....
Items per page:
1 - 10 of 564